Mizuho Securities analyst Difei Yang reiterated a Hold rating on RegenXBio (NASDAQ: RGNX) today and set a price target of $29. The company’s shares closed yesterday at $39.65, close to its 52-week high of $42.
Yang said:
“We see the company’s NAV Technology Platform as a key high-quality asset that will continue to drive value for Regenxbio. However, we believe the value is fully priced in at the moment and we reiterate our Neutral rating on the stock.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.2% and a 50.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $49.75.
See today’s analyst top recommended stocks >>
Based on RegenXBio’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16 million. In comparison, last year the company had a GAAP net loss of $21.99 million.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
